Search

Your search keyword '"Porter, Arthur T."' showing total 175 results
Start Over Author "Porter, Arthur T."
175 results on '"Porter, Arthur T."'

12. Contributors

Author

Abrams, Ross A., primary, Alonso-Basanta, Michelle, additional, Anderson, Bethany M., additional, Anderson, Kenneth C., additional, Ang, K. Kian, additional, Arthur, Douglas W., additional, Avey, Gregory D., additional, Ballo, Matthew T., additional, Barker, Christopher A., additional, Baszkowsky, Lawrence S., additional, Beitler, Jonathan J., additional, Blackstock, A. William, additional, Bogart, Jeffrey A., additional, Bonner, James A., additional, Bourland, J. Daniel, additional, Breneman, John, additional, Brown, Paul D., additional, Buchholz, Thomas A., additional, Buchsbaum, Jeffrey C., additional, Burke, Michael, additional, Buskirk, Steven J., additional, Calderwood, Stuart K., additional, Callister, Matthew D., additional, Calvo, Felipe A., additional, Cannon, George M., additional, Catton, Charles, additional, Chabner, Bruce A., additional, Chan, Michael D., additional, Chao, Sam T., additional, Chung, Peter, additional, Coen, John J., additional, Constine, Louis S., additional, Corn, Benjamin W., additional, Covens, Allan, additional, Craciunescu, Oana, additional, Creutzberg, Carien L., additional, Crook, Juanita, additional, Curran, Walter J., additional, Czito, Brian G., additional, Das, Shiva, additional, David, Marc, additional, DeLaney, Thomas F., additional, Dewhirst, Mark, additional, Dickie, Colleen, additional, Dome, Jeffrey S., additional, Donohue, John H., additional, Duprez, Thierry, additional, Dutta, Pinaki, additional, Efstathiou, Jason A., additional, Eisbruch, Avraham, additional, Feng, Mary, additional, Fernandes, Rui P., additional, Fielding, Julia R., additional, Fleming, Gini F., additional, Foote, Robert L., additional, Fraass, Benedick A., additional, Garden, Adam S., additional, Gentry, Lindell R., additional, Ghilezan, Michel, additional, Gospodarowicz, Mary K., additional, Grau, Cai, additional, Grégoire, Vincent, additional, Greven, Craig M., additional, Greven, Kathryn McConnell, additional, Gunderson, Leonard L., additional, Haddock, Michael G., additional, Hamoir, Marc, additional, Harari, Paul M., additional, Hay, Ian D., additional, Hertzfeld, Kara, additional, Hogg, David, additional, Horsman, Michael R., additional, Hudgins, Patricia A., additional, Hudson, Melissa M., additional, Jewells, Valerie S., additional, Jolly, Shruti, additional, Jones, Glenn, additional, Kalapurakal, John A., additional, Khandani, Amir H., additional, Khuntia, Deepak, additional, Knox, Susan J., additional, Koh, Wui-Jin, additional, Krasin, Matthew J., additional, Kuban, Deborah A., additional, Kun, Larry E., additional, LaCasce, Ann S., additional, Laramore, George E., additional, Lassman, Andrew B., additional, Laufer, Marsha, additional, Lavigne, Ruth, additional, Lawrence, Theodore S., additional, Lawton, Colleen A., additional, Lee, Nancy, additional, Lengelé, Benoît, additional, Levin, William P., additional, Lin, Alexander, additional, Lindegaard, Jacob C., additional, Mackillop, William J., additional, Mahindra, Anuj, additional, Mancuso, Anthony A., additional, Marcus, Karen J., additional, Marks, Lawrence B., additional, Martenson, James A., additional, Martinez, Alvaro A., additional, Mauch, Peter, additional, Mazeron, Jean-Jacques, additional, McHaffie, Derek R., additional, Mehta, Minesh P., additional, Mendenhall, William M., additional, Merchant, Thomas E., additional, Meredith, Ruby F., additional, Michalski, Jeff, additional, Milano, Michael T., additional, Bonner Millar, Lara P., additional, Minsky, Bruce D., additional, Moore, David H., additional, Morrison, William H., additional, Newman, Jason G., additional, Ng, Andrea K., additional, Nordsmark, Marianne, additional, Offerman, Shannon, additional, Okunieff, Paul, additional, O’Neil, Bert, additional, O'Sullivan, Brian, additional, Ove, Roger, additional, Overgaard, Jens, additional, Parker, Alexander S., additional, Paulussen, Michael, additional, Petersen, Ivy A., additional, Peterson, Jennifer L., additional, Pisansky, Thomas M., additional, Porter, Arthur T., additional, Potters, Louis, additional, Pugh, Thomas J., additional, Quon, Harry, additional, Raben, David, additional, Recht, Abram, additional, Rengan, Ramesh, additional, Roberts, Kenneth B., additional, Rockhill, Jason K., additional, Rödel, Claus, additional, Rodriguez-Galindo, Carlos, additional, Rogers, C. Leland, additional, Russell, Anthony H., additional, Russo, Suzanne, additional, Sandlund, John T., additional, Sandow, Pamela R., additional, Sargent, Daniel J., additional, Sartor, Carolyn I., additional, Schifter, Dan, additional, Schild, Steven E., additional, Schuck, Andreas, additional, Seegenschmiedt, Michael Heinrich, additional, Shah, Anand P., additional, Shaw, Edward G., additional, Sheikh, Arif, additional, Shipley, William U., additional, Siker, Malika L., additional, Siu, Lillian L., additional, Small, William, additional, Smith, Benjamin D., additional, Stauffer, Paul, additional, Stevenson, Mary Ann, additional, Stieber, Volker W., additional, Suh, John H., additional, Supko, Jeffrey G., additional, Tan, Winston W., additional, Tepper, Joel E., additional, Thomas, Charles R., additional, Thomas, Gillian M., additional, Thrall, Donald, additional, Tomé, Wolfgang, additional, Tsang, Richard W., additional, Valentini, Vincenzo, additional, van den Bendt, Martin J., additional, Van der Zee, Ate G.J., additional, Veness, Michael J., additional, Vicini, Frank A., additional, Vicus, Danielle, additional, Vujaskovic, Zeljko, additional, Wadsworth, J. Trad, additional, Wagner, Henry, additional, Warde, Padraig R., additional, Wehle, Michael J., additional, Weil, Robert J., additional, Weiss, Jared, additional, Weiss, Lawrence, additional, Werning, John W., additional, Willett, Christopher G., additional, Willey, Christopher D., additional, Wilson, Lynn D., additional, Wolden, Suzanne, additional, Wong, Jeffrey Y.C., additional, Wong, William W., additional, Wu, Wenting, additional, Yahalom, Joachim, additional, You, Y. Nancy, additional, Zeman, Elaine M., additional, and Zietman, Anthony L., additional

Published
2012
Full Text
View/download PDF

13. Metastatic Disease

Author

Okunieff, Paul, primary, Milano, Michael T., additional, Porter, Arthur T., additional, and David, Marc, additional

Published
2012
Full Text
View/download PDF

21. Hyperbaric oxygen therapy for radiation-induced brain injury in children

Author

Chuba, Paul J., Aronin, Patricia, Bhambhani, Kanta, Eichenhorn, Michael, Zamarano, Lucia, Cianci, Paul, Muhlbauer, Michael, Porter, Arthur T., and Fontanesi, James

Subjects
Radiotherapy -- Complications, Hyperbaric oxygenation -- Health aspects, Brain damage -- Care and treatment, Health
Published
1997

22. Brachytherapy for prostate cancer

Author

Porter, Arthur T., Blasko, John C., Grimm, Peter D., Reddy, Sarada M., and Ragde, Haakon

Subjects
Prostate cancer -- Care and treatment, Radioisotope brachytherapy -- Methods, Health
Published
1995

25. 12(S)-HETE enhancement of prostate tumor cell invasion: selective role of PKC(alpha)

Author

Liu, Bin, Maher, Robert J., Hannun, Yusuf A., Porter, Arthur T., and Honn, Kenneth V.

Subjects
Prostate cancer -- Metastasis, Cancer invasiveness -- Physiological aspects, Health
Abstract

Background: Prostate carcinoma has become the second most fatal cancer in American men. In Dunning R3327 rat prostate adenocarcinoma cells, elevated invasiveness positively correlates with metastatic potential. However, the mechanism(s) responsible for regulation of tumor cell motility and invasion is poorly understood. We have reported that a lipoxygenase metabolite of arachidonic acid, 12(S)-hydroxyeicosatetraenoic acid [12(S)-HETE], augments tumor cell metastatic potential through activation of protein kinase C (PKC). Purpose: We proposed to determine the effect of 12(S)-HETE on the motility and invasion of low-metastatic rat prostate AT2.1 tumor cells and the effect of 12(S)-HETE activation of specific PKC isoform(s) in these processes. Methods: The motility of AT2.1 cells was determined by the colloidal gold phagokinetic track assay and the invasiveness measured as their ability to invade through basement membrane Matrigel-coated filters. Expression of PKC isoforms was determined by Western blotting of the whole cell lysate with isoform-specific anti-PKC antibodies. Cytosol and membrane fractions were prepared and the subcellular distribution of PKC was analyzed by Western blotting and activity assay. The effect of 12(S)-HETE on cell proliferation was examined. Data were analyzed for significance of difference with the two-sampled, two-sided Student's t test. Results: 12(S)-HETE increased the motility and invasion of AT2.1 cells, and this 12(S)-HETE-increased motility and invasion were inhibited by a selective PKC inhibitor, calphostin C, as well as a [Ca.sup.2] chelator, bis-(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid/tetra(acetoxy-methyl)ester. AT2.1 cells expressed the PKC isoforms [alpha] and [delta], and 12(S)-HETE increased the membrane association of PKC[alpha] but not [delta]. Further, the motility and invasion of AT2.1 cells were increased by thymelea toxin, a selective activator of PKC[alpha] over PKC[delta]. Conclusion: 12(S)-HETE augments the invasiveness of AT2.1 cells via selective activation of PKC[alpha]. Implications: 12(S)-HETE modulation of PKC[alpha] invasiveness may be an important mechanism of action for the regulation of the invasive potential of rat prostate carcinoma cells, and the 12-lipoxygenase enzyme and/or PKC[alpha] may serve as key targets for the development of anti-invasive agents useful for combating the spread of prostate cancer. [J Natl Cancer Inst 86:1145-1151, 1994]

Published
1994

26. Prostate brachytherapy: an overview

Author

Porter, Arthur T. and Forman, Jeffrey D.

Subjects
Prostate cancer -- Care and treatment, Radioisotope brachytherapy -- Usage, Radiotherapy -- Methods, Health
Abstract

Background. Prostate brachytherapy represents one of the oldest techniques of using radiation therapy to treat prostate cancer. Over the past 10 years, there have been major changes in the types of prostate brachytherapy that can be performed with the introduction of new radioactive isotopes, new afterloading techniques, and an improved understanding of the radiobiology associated with differing dose rates. Methods. Prostate brachytherapy can be divided into temporary implantation using high activity sources such as iridium-192, or permanent brachytherapy using the interstitial implantation of iodine-125 or palladium-103 sources. There are various techniques that can be used to actually insert the radioactive material into the prostate. This can be done as an open or closed procedure and can be performed via a suprapubic or a perineal retropubic approach. The use of remote afterloading has substantially reduced the radiation protection problems associated with manually loaded radioactive sources. Results. Results using brachytherapeutic isotopes in the treatment of prostate cancer have been variable, but it appears that using the higher dose rate sources and delivering a high relative integral dose to the prostate can result in improved histologic control of prostate cancer. In patients with aggressive prostate cancer, the use of iodine-125 permanent implantation has not been successful. Conclusions. The role of brachytherapy in the treatment of prostate cancer remains an exciting alternative in the management of prostate cancer. Its role is becoming more defined in the treatment of large, bulky prostatic neoplasms as a way of improving the dose distribution achieved between normal and tumor tissue. Cancer 1993; 71:953-8.

Published
1993

27. Prostate-specific antigen: monitoring the response of carcinoma of the prostate to radiotherapy with a new tumor marker

Author

Dundas, George S., Porter, Arthur T., and Venner, Peter M.

Subjects
Prostate cancer -- Care and treatment, Tumor markers, Tumor antigens -- Research, Health
Abstract

Tumor markers are substances, usually proteins, that are preferentially associated with tumor cells rather than normal tissues. In many cases, the appearance of increased levels of a tumor marker in the blood precedes the clinically detectable recurrence of a tumor in a patient. The clinical value of prostate-specific antigen (PSA), a sensitive marker for cancer of the prostate, was analyzed among 110 patients undergoing radiotherapy for local prostate cancer. The blood level of PSA was elevated in 83 percent of the patients with prostate cancer prior to treatment. Nine patients suffered recurrent disease subsequent to radiation treatment; in none of these patients did the PSA level return to normal after treatment. However, among the 101 patients who did not experience recurrence, the PSA level of 74 returned to normal. The possibility that the remaining patients with abnormal PSA levels may develop disease recurrence is being monitored as follow-up continues. The failure of PSA to return to normal levels within six months of treatment may be considered to be a sign of possible treatment failure; these patients may be candidates for early treatment intervention. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1990

35. Book reviews

Author

Law, H. D., Clark, Burton R., Niblett, Roy, Porter, Arthur T., and Brennan, John

Published
1974
Full Text
View/download PDF

38. Therapeutic Strategies for Localized Prostate Cancer II: Perineal Prostatectomy, X-Rays, Protons, Neutrons, and Combination Brachytherapy

Author

Weil, Michael D, Porter, Arthur T, Beyer, David C, Albert, Peter S, Chinn, Douglas, and Harris, Michael J

Subjects
10th International Prostate Cancer Update
Abstract

Application of improved imaging, diagnostic, and computer techniques is beginning to have an impact on the management of localized prostate cancer. It is possible to perform a range of surgical and radiation procedures with less morbidity than in the past. The changes in therapy for patients with localized disease derive from better knowledge of anatomy for invasive procedures and optimization of virtual planning for noninvasive methods. Perineal prostatectomy and combinations of beam and seed radiation offer both patient and physician reasonable therapeutic options.

Published
2000

39. Treating Brain Cancers

Author

Maruyama, Yosh, Fontanesi, James, Porter, Arthur T., Wierzbicki, Jacek G., and Gaspar, Laurie

Published
1994

41. Prostate secretory protein (PSP94) suppresses the growth of androgen-independent prostate cancer cell line (PC3) and xenografts by inducing apoptosis

Author

Garde, Seema V., primary, Basrur, Vathsala S., additional, Li, Li, additional, Finkelman, Malcolm A., additional, Krishan, Awtar, additional, Wellham, Larry, additional, Ben-Josef, Edgar, additional, Haddad, Maher, additional, Taylor, John D., additional, Porter, Arthur T., additional, and Tang, Dean G., additional

Published
1999
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results